TWiV 986: Clinical update with Dr. Daniel Griffin - podcast episode cover

TWiV 986: Clinical update with Dr. Daniel Griffin

Feb 25, 202343 minEp. 986
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

In his weekly clinical update Dr. Griffin discusses the efficacy and safety of two RSV vaccines in older adults, health care vaccine mandate remains as some push for an end, past SARS-CoV-2 infection protection against re-infection, a third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model, effect of higher-dose Ivermectin for 6 Days vs placebo on time to sustained recovery in outpatients with COVID-19, viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong, serological response to vaccination in post-acute sequelae of COVID, sex differences in cardiovascular complications and mortality in hospital patients with COVID-19, association of COVID-19 vaccination with risk for incident diabetes after COVID-19, postacute sequelae of SARS-CoV-2 in university setting, the CDC’s long-Covid deception, and podcast companies, once walking on air, feel the strain of gravity.

Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
TWiV 986: Clinical update with Dr. Daniel Griffin | This Week in Virology podcast - Listen or read transcript on Metacast